Drug Discovery

NVIDIA BioNeMo revolutionizes drug discovery with AI, offering new models for genomics, proteomics, and drug design for faster, smarter healthcare solutions.

NVIDIA BioNeMo: A Game Changer in Drug Discovery

NVIDIA’s at it again! This time with an update to BioNeMo. They’ve added some fresh tools to their AI kit, making drug discovery faster and smarter. Let’s dive into what this means for the future of medicine.

What’s New with BioNeMo?
  • Fresh AI Tools: NVIDIA’s loaded BioNeMo with new models and services. These can peek into DNA, figure out protein changes, and tell you what’s happening in cells based on RNA.
  • Easy Access: Now, these tools aren’t just stuck in a lab. They’re available through NVIDIA NIM and AI Enterprise, and soon, you’ll find them on AWS HealthOmics too.
  • Meet DNABERT: This is a cool new model that gets the lowdown on genome functions and mutations.
  • scBERT in the House: Got single-cell RNA data? scBERT can handle it, helping predict gene impacts and identifying cell types. It’s a big deal for tackling complex diseases.
  • EquiDock: This one’s about predicting how proteins hang out together in 3D. It’s key for designing new drugs that fit like a glove.
NIM’s Got Your Back
  • DiffDock: Imagine being able to see how a drug fits with its target. That’s DiffDock for you.
  • ESMFold: Need to know a protein’s shape? ESMFold’s got you covered.
  • MolMIM: It’s all about cooking up the best drug candidates out there.
Why It Matters

Companies like Astellas Pharma and Terray Therapeutics are already using BioNeMo. It’s proving to be a powerhouse in speeding up drug discovery and making it cost-effective.

Looking Ahead

We’re looking at a future where treatments are not just effective but also arrive faster and tailor-made. NVIDIA’s pushing the envelope, ensuring researchers have what they need to tackle today’s biggest health challenges. Here’s to more breakthroughs and a healthier tomorrow.

NVIDIA BioNeMo: A Game Changer in Drug Discovery Read More »

AI-driven biotech drug discovery

Alphabet’s AI-driven drug discovery Lab Isomorphic Lands Big Pharma Deals

Alphabet’s Isomorphic, an AI biotech startup, is making headlines with major pharmaceutical partnerships. Let’s dive into this exciting development in the AI and biotech world.

Isomorphic’s Big Pharma Breakthrough

Isomorphic has just inked deals with giants Eli Lilly and Novartis. The terms? An impressive $83 million upfront and potential milestone payments up to $2.9 billion. That’s huge!

Leveraging AlphaFold for Drug Discovery

Here’s where it gets interesting: Isomorphic uses Google DeepMind’s AlphaFold model. This is all about using AI to speed up drug discovery, a game-changer in pharmaceuticals.

Rapid Rise in AI Biotech

Since its start in November 2021, Isomorphic has been on a fast track. In less than a year, they’ve positioned themselves as key players in AI biotech.

Leadership and Growth

  • At the Helm: Demis Hassabis, CEO of Google DeepMind, is leading the charge. His expertise in AI is steering Isomorphic towards success.
  • Team and Locations: About 90 employees are fueling Isomorphic’s growth, based in London and Lausanne, Switzerland.

The Bottom Line

Isomorphic’s recent partnerships mark a significant milestone in AI-driven drug discovery. With its advanced use of AI and rapid growth, the company is set to revolutionize how we approach pharmaceuticals. Keep an eye on Isomorphic – they’re pushing boundaries in the exciting convergence of AI and biotech! 🚀💊🤖

Alphabet’s AI-driven drug discovery Lab Isomorphic Lands Big Pharma Deals Read More »